According to the results of a single-arm, multicenter phase 2 trial in JAMA Oncology, low-dose erlotinib may be a safe and effective option for frail or elderly patients with EGFR mutation-positive NSCLC.

Based on monotherapy data from an open-label, multi-center, single-arm study of 105 adults with platinum-sensitive and platinum-resistant SCLC that progressed after platinum-based chemotherapy, the FDA granted accelerated approval to lurbinectedin (Zepzelca; Jazz Pharmaceuticals and PharmaMar).

Published in Practical Radiation Oncology, the recommendations from the American Society for Radiation Oncology (ASTRO) are based on a systematic literature review, consensus, and system for grading evidence quality and recommendation strength.

As a result of COVID-19, many physicians had to provide telemedicine services in a matter of weeks, if not days. A major accomplishment, for sure. But are you getting paid for your hard work? Read on to find out how you can ensure you are being compensated for the work you’ve been doing.

Based on the data from the ATTRACTION-3 clinical trial, the FDA approved nivolumab (Opdivo; BMS) for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) who previously received fluoropyrimidine- and platinum-based chemotherapy.

After tobacco use and excess body weight, alcohol consumption is the third major modifiable cancer risk factor. In its latest guidelines, the American Cancer Society has tightened its grip on its recommendations, basically telling people not to drink alcohol at all if they want to prevent cancer risk.